Managements of second successful pregnancies of women with antiphospholipid syndrome

Abstructs

Managements of second successful lipid syndrome

pregnancies

91

of women with antiphospho-

Rabiye Babalioglu”, Lemi Ibrahimoglub, Ahmet Gul”, Selim Badurd, Nevin &men”, Bilhan Sidal”. aDeparfment of Gynaecology,lObstetrics, Vaklf Gureba Teaching Hospital, Istanbul, Turkey; ‘Depart~~e~t of Gynaecoiogy/ obstetrics, rstanbu~ University, ~ed~~a~ School, asfanb~i, Turkey; ‘Depart ment of ~he~~athology, Istanbul University, ~edica~ Schoo~~ Istanbul, Turkey; ‘Depart~~ent of ~icrobio~ogy, Istanbul University, medical School, Istanbul, Turkey The second pregnancies of 3 patients (ages of 33, 36, 20 years old) who had recurrent second trimester fetal deaths and antiphospholipid syndrome, and had had one live birth after managements, were presented in this study. During the investigation of other accompanying pathology, one patient was found to be systemic lupus erythematosus. During the first successful pregnancies, in all three patients, low dose acetyl salisylic acid (80 mgjday) and prednisolone (lo-20 mg/day) had been used. During the second pregnancies, except SLE patient, only low dose acetyl salisylic acid (80 mg/day) was used. Antiphospholipid antibody titers were declined during pregnancy. In SLE patient, at 35th gestational week, only mild thrombocytopenia developed. Deliveries occurred at 37-39th gestational weeks. Newborn babies had no problem except one of SLE patient who had mild thrombocytopenia and elevated antiDNA titer. Also maternal status did not worsen during postpartum period. According to these three patients’ successful second pregnancies, it was suggested that antiphospholipid antibody titers at the beginning and during pregnancies, and underlying pathologies can be important factors to manage the maternal and fetal status. Keywords: Antiphospholipid

syndrome;

Meta-analysis

immune globulin for recurrent pregnancy loss.

of intravenous

Second successful pregnancies

T. Flint Porter, Robert M. Silver, D. Ware Branch, James R. Scott. Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, USA Objective: To determine whether treatment of recurrent pregnancy loss patients (RPL) with intravenous ~??z~une globulin (IVIG) improves the chance of a live birth. Study Design: beta-analysts of individual patient data. We obtained patient information from three centers with published results from random-